Huawei has officially announced its first continuous glucose monitoring (CGM) system, the Huawei Weigan G1. The device provides 24/7 continuous glucose monitoring and supports data viewing across multiple devices as well as abnormal glucose alerts. Utilizing subcutaneous soft needle technology, it converts tissue fluid glucose into blood glucose readings, achieving a MARD (Mean Absolute Relative Difference) value below 10% with a data lag of 5 to 15 minutes. Its hidden needle design allows users to swim while wearing it, and a single sensor can last approximately two weeks. The product is classified as a Class III medical device under registration certificate No. National Equipment Registration 20263072228 — marking the first time Huawei has obtained Class III medical device certification in the health monitoring field. Huawei has long been engaged in glucose monitoring, having previously launched a smartwatch supporting hyperglycemia risk assessment, with related device R&D spanning four years.